ANDREW TIMPSON
@Silverarc Capital Management, Llc
Latest period2024 - Q3ReportedManaged Assets$445.291MTotal holdings69
Assets growth rate5.06%Assets growth rate (2-Q avg)11.39%Continuous growth in asset value6 quarters
Portfolio positions
This chart displays the top 10 holdings in Silverarc Capital Management, Llc's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 69 positions.
Assets under management
The assets under management (AUM) of Silverarc Capital Management, Llc over the past 10 years (40 quarters) show continuous growth in total asset value over the last 6 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 445.291M in assets, with a quarterly growth rate of 5.06% and a 2-quarter average growth rate of 11.39%. The portfolio is managed by ANDREW TIMPSON, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
CNTACentessa Pharmaceuticals Plc
| 2.68% | $11.906M 744,592 shares@ $15.99 avg price | New Position |
PTGXProtagonist Therapeutics Inc
| 1.49% | $6.6M 146,657 shares@ $45.0 avg price | New Position |
BNTXBiontech Se
| 0.7% | $3.098M 26,083 shares@ $118.78 avg price | New Position |
RLAYRelay Therapeutics Inc
| 0.67% | $2.968M 419,242 shares@ $7.08 avg price | New Position |
ZVRAZevra Therapeutics Inc
| 0.55% | $2.429M 350,000 shares@ $6.94 avg price | New Position |
BIOABioage Labs Inc
| 0.47% | $2.08M 100,000 shares@ $20.8 avg price | New Position |
UNCYUnicycive Therapeutics Inc
| 0.37% | $1.632M 4M shares@ $0.41 avg price | New Position |
XNCRXencor Inc
| 0.35% | $1.518M 75,507 shares@ $20.12 avg price | New Position |
EVGNEvogene Ltd
| 0.22% | $945,480 307,974 shares@ $3.07 avg price | New Position |
APLTApplied Therapeutics Inc
| 0.2% | $850,000 100,000 shares@ $8.5 avg price | New Position |